Jump to navigation

Home

Search form

Main menu

  • HOME
  • ABOUT
    • Founder
    • Optimata Team
    • Publications
    • Awards Grants and Projects
    • Exhibitions and Conferences
  • PREDICARE
    • Current Standard of Care
    • The PrediCare Product
    • Optimizing Treatment Switch
    • Technology
  • CONTACT US
  • SEARCH

Change Lang

  • 简体中文 简体中文
  • English English
title=

PrediCare

PREDICARE

  • Current Standard of Care
  • The PrediCare Product
  • Optimizing Treatment Switch
  • Technology
  • 简体中文 简体中文
  • Current Standard of Care

    Nowadays, the standard-of-care (SOC) treatment options of advanced stage (IIb and IV) solid cancers (e.g., lung, breast , colon cancer) include different therapeutic options, ranging from standard chemotherapies to novel targeted therapeutics or immunotherapies.

     

    READ MORE
  • The PrediCare Product

    PrediCare is a novel software-based treatment navigation tool, predicting the patient’s disease progression moment. This moment is critical in the patient’s therapeutic timeline, being the key event controlling the change of the treatment plan. PrediCare is designed to be applied in the individual patient treatment course, after each radiological assessment of the tumor, and prior to the next scheduled assessment.

     

    READ MORE
  • Optimizing Treatment Switch

    PrediCare facilitates a treatment line switch just prior to an imminent disease progression. This policy adheres to the National Comprehensive Cancer Network (NCCN) guideline, e.g., for switch maintenance therapy in non-small cell lung cancer, but in contrast to the latter modality, PrediCare enables optimization of the timing of the switch in the treatment line, and thus contributes to better patient outcomes.


    READ MORE
  • Technology

    The technology of PrediCare relies on an algorithm which integrates patient level clinical information with a newly-developed machine-learning methodology, which extracts and amplifies biomarker signals for a forthcoming progression event.

     

     

    READ MORE